NMOSD Treatment

Neuromyelitis optica spectrum disorder (NMOSD) is characterized by severe, relapsing attacks that carry a high risk of cumulative disability if left untreated. Unlike multiple sclerosis, NMOSD does not have a progressive phase — disability accumulates exclusively through incomplete recovery from relapses. This makes both prompt acute treatment and effective long-term relapse prevention essential. The therapeutic landscape for NMOSD has been transformed by clinical trials demonstrating the efficacy of targeted biologic agents, with three drugs now FDA-approved specifically for AQP4-IgG-positive NMOSD.

Treatment of Acute Attacks

Prompt acute-treatment initiation is fundamental in AQP4-NMOSD because treatment delay has been associated with poorer recovery and worse outcomes. Unlike MS, where relapses are often mild and self-limited, NMOSD attacks frequently cause severe disability, and residual deficits from poorly treated attacks are the primary driver of long-term disability.

High-Dose Corticosteroids

High-dose IV corticosteroids remain the first-line treatment for acute NMOSD attacks:

Plasma Exchange (PLEX)

Plasma exchange has gained increasing use in the treatment of NMOSD attacks. Key principles include:

• Regimen: 5–7 sessions on alternate days, can be administered concurrently with corticosteroids
• Timing: If administered with corticosteroids, schedule the steroid infusion soon after the plasma exchange session
• Early initiation is critical: Consider starting PLEX on day 3–4 after IV methylprednisolone initiation in patients with severe disability
• Do not wait for antibody results: The efficacy of PLEX for severe CNS demyelinating attacks was proven in a pivotal randomized, sham-controlled trial (1999) before the discovery of AQP4 and MOG antibodies
• Generally safe; may rarely induce hypotension (use caution in patients with cardiac disease)

Intravenous Immunoglobulin (IVIg)

IVIg may be considered on an empiric basis, though evidence supporting its use in acute attacks is limited to retrospective studies:

• Dosing: 0.4 g/kg/day for 5 consecutive days
• May be considered for incomplete recovery after corticosteroids and PLEX
• More commonly used in pediatric patients
• Common complications: headache, hypertension during infusions

Rescue Therapies

Rescue therapies may rarely be necessary for severe attacks refractory to high-dose corticosteroids, PLEX, and IVIg:

Maintenance Therapy for AQP4-NMOSD

Long-term treatment aims to prevent relapses and disability accumulation. The need for relapse prevention is clear in AQP4-NMOSD because the risk of relapses after the presenting attack is nearly universal (>90% of patients have relapsing disease). Maintenance therapy should be initiated at or near the time of diagnosis.

FDA-Approved Therapies

Three biologic agents are currently FDA-approved for AQP4-IgG-positive NMOSD in the United States:

Satralizumab (Anti-IL-6 Receptor)

Satralizumab is a recycling monoclonal antibody that blocks the IL-6 receptor, a key cytokine in NMOSD pathogenesis that drives Th17 differentiation and plasmablast survival. It has been proven effective for relapse prevention in AQP4-NMOSD, particularly in AQP4-IgG-seropositive patients where the treatment effect was most robust. Satralizumab is administered subcutaneously, offering convenience over IV regimens. It is also currently being studied for relapse prevention in MOGAD.

Inebilizumab (Anti-CD19)

Inebilizumab targets CD19, a B-cell surface marker with broader expression than CD20. Unlike CD20 inhibitors (e.g., rituximab), inebilizumab depletes a wider spectrum of B cells, including antibody-producing plasmablasts and plasma cells that lack CD20 expression. After induction with 300 mg given 2 weeks apart, the drug is reinfused at fixed 6-month intervals. Inebilizumab demonstrated significant relapse reduction in the N-MOmentum trial. It has not been studied for the treatment of MOGAD.

Eculizumab (Anti-C5 Complement)

Eculizumab inhibits the terminal complement cascade by blocking C5 cleavage, preventing formation of the membrane attack complex — a key effector of astrocyte injury in AQP4-NMOSD. It was shown to be highly effective in the PREVENT trial, with a 94% reduction in relapse risk. Key considerations:

• Requires meningococcal vaccination at least 2 weeks before initiation
• Frequent IV infusions (every 2 weeks) are necessary for maintenance
• Ravulizumab is a longer-acting C5 inhibitor administered IV every 8 weeks (weight-dependent dosing), offering a more practical alternative
• Complement inhibitors have not been studied in MOGAD

Rituximab (Anti-CD20)

Worldwide, rituximab is the most commonly used treatment for AQP4-NMOSD, providing effective relapse prevention in approximately 60–70% of patients:

Tocilizumab (Anti-IL-6 Receptor)

Tocilizumab is another IL-6 receptor inhibitor administered IV at 8 mg/kg every 4 weeks. In a phase 2 trial, it was proven superior to azathioprine in preventing AQP4-NMOSD relapses. It may be considered as an alternative, particularly in regions where the FDA-approved agents are unavailable.

Oral Immunosuppressants

Azathioprine and mycophenolate mofetil have shown moderate effectiveness in preventing relapses in both NMOSD and MOGAD. These drugs typically require 3–6 months to become fully effective, necessitating bridging therapy with oral corticosteroids. They can be considered when more effective biologic options are unavailable.

Treatment Selection and Sequencing

Symptomatic Management

Painful Tonic Spasms

Painful tonic spasms are common in AQP4-NMOSD myelitis and consist of brief, intensely painful episodes of involuntary muscle contraction. They typically respond well to carbamazepine 150–200 mg twice daily. Other anticonvulsants (oxcarbazepine, gabapentin) may also be used.

Other Symptomatic Considerations

• Neuropathic pain: Gabapentin, pregabalin, duloxetine, or amitriptyline
• Spasticity: Baclofen, tizanidine; botulinum toxin for focal spasticity
• Bladder dysfunction: Common after myelitis; urodynamic evaluation and appropriate pharmacotherapy
• Visual rehabilitation: Low-vision aids and referral for patients with residual visual deficits from optic neuritis
• Fatigue: Nonpharmacologic strategies; energy conservation, exercise programs

Emerging Therapies

• Aquaporumab: A humanized monoclonal antibody targeting the AQP4 water channel with a modified Fc fragment that prevents complement activation — it competes with pathogenic AQP4-IgG for binding sites without causing tissue damage
• Ravulizumab: A longer-acting C5 complement inhibitor (every 8 weeks vs. every 2 weeks for eculizumab), offering improved convenience with similar mechanism
• Additional complement pathway inhibitors and B-cell targeting agents are in various stages of development

Prognosis

The prognosis of AQP4-NMOSD has improved substantially with the advent of effective targeted therapies. In the pre-treatment era, 5-year mortality was approximately 30%, largely driven by respiratory failure from high cervical myelitis or brainstem attacks. With current therapies, the majority of patients can achieve relapse-free status, though disability from early attacks before treatment initiation remains a significant concern. This underscores the importance of early and accurate diagnosis, prompt acute treatment, and rapid initiation of maintenance immunotherapy.

References

1. Sechi E. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. Continuum (Minneap Minn). 2024;30(4):1057-1090.
2. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614-625.
3. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum). Lancet. 2019;394(10206):1352-1363.
4. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114-2124.
5. Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders: a systematic review. J Neurol Sci. 2020;415:116892.
6. Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391-401.
7. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46(6):878-886.